Literature DB >> 19693538

Adipocytokines and squamous cell carcinoma of the esophagus.

Takako Eguchi Nakajima1, Yasuhide Yamada, Tetsutaro Hamano, Koh Furuta, Ichiro Oda, Hoichi Kato, Ken Kato, Tetsuya Hamaguchi, Yasuhiro Shimada.   

Abstract

PURPOSE: Adipocytokines are adipocyte-secreted hormones associated with some malignancies. It has been reported that the impaired response of adipocytokines to body weight loss may play a role in the pathogenesis of cancer-induced cachexia. We investigated the association between adipocytokines with squamous cell carcinoma of the esophagus (SCCE).
METHODS: The levels of body mass index (BMI) and adiponectin, leptin, resistin, visfatin and C-peptide in the blood at diagnosis were measured in 117 SCCE patients and 117 age- and sex-matched controls. Logistic regression models were employed to estimate odds ratio. One-way analysis was performed to examine the prevalence of variables between two or more groups. A non-parametric Spearman correlation test was conducted to examine the associations between BMI and other variables.
RESULTS: Adiponectin and BMI levels were significantly lower, and resistin level was significantly higher in the patients on multivariate analysis (P = 0.01, <0.01 and <0.01 respectively). BMI gradually decreased with stage progression, and resistin level gradually increased with stage progression (P < 0.01 for both). The inverse correlation between BMI and adiponectin was comparatively strong in the controls, but was weak in the patients. Leptin showed comparatively strong correlation with BMI in the controls, but was weakly correlated in the patients. The correlation between BMI and resistin or C-peptide was demonstrated weakly only in the controls, and visfatin did not correlate with BMI.
CONCLUSIONS: Resistin may be a biomarker for the progression of SCCE. In addition, the impaired responses to body weight loss of adiponectin and leptin in the patients with SCCE were suggested.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19693538     DOI: 10.1007/s00432-009-0657-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  23 in total

1.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.

Authors:  Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa
Journal:  Biochem Biophys Res Commun       Date:  1999-04-02       Impact factor: 3.575

Review 2.  Insulin, insulin-like growth factors and colon cancer: a review of the evidence.

Authors:  E Giovannucci
Journal:  J Nutr       Date:  2001-11       Impact factor: 4.798

3.  Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study.

Authors:  Esther K Wei; Edward Giovannucci; Charles S Fuchs; Walter C Willett; Christos S Mantzoros
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

4.  Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages.

Authors:  T Yokota; K Oritani; I Takahashi; J Ishikawa; A Matsuyama; N Ouchi; S Kihara; T Funahashi; A J Tenner; Y Tomiyama; Y Matsuzawa
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

5.  Plasma adiponectin and gastric cancer.

Authors:  Makoto Ishikawa; Joji Kitayama; Shinsuke Kazama; Takeyuki Hiramatsu; Kenji Hatano; Hirokazu Nagawa
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

Review 6.  Obesity and cancer.

Authors:  Eugenia E Calle; Michael J Thun
Journal:  Oncogene       Date:  2004-08-23       Impact factor: 9.867

7.  Adiponectin and the systemic inflammatory response in weight-losing patients with non-small cell lung cancer.

Authors:  Nigel B Jamieson; Duncan J F Brown; A Michael Wallace; Donald C McMillan
Journal:  Cytokine       Date:  2004 Jul 21-Aug 7       Impact factor: 3.861

8.  Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages.

Authors:  Masahiro Kumada; Shinji Kihara; Noriyuki Ouchi; Hideki Kobayashi; Yoshihisa Okamoto; Koji Ohashi; Kazuhisa Maeda; Hiroyuki Nagaretani; Ken Kishida; Norikazu Maeda; Azumi Nagasawa; Tohru Funahashi; Yuji Matsuzawa
Journal:  Circulation       Date:  2004-04-19       Impact factor: 29.690

9.  Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients.

Authors:  Anna Kumor; Piotr Daniel; Mirosława Pietruczuk; Ewa Małecka-Panas
Journal:  Int J Colorectal Dis       Date:  2008-11-01       Impact factor: 2.571

10.  Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers.

Authors:  Barbara E Wolfe; David C Jimerson; Christine Orlova; Christos S Mantzoros
Journal:  Clin Endocrinol (Oxf)       Date:  2004-09       Impact factor: 3.478

View more
  15 in total

Review 1.  The role of adiponectin in cancer: a review of current evidence.

Authors:  Maria Dalamaga; Kalliope N Diakopoulos; Christos S Mantzoros
Journal:  Endocr Rev       Date:  2012-04-30       Impact factor: 19.871

2.  Abdominal obesity increases risk for esophageal cancer: a nationwide population-based cohort study of South Korea.

Authors:  Jae Ho Cho; Cheol Min Shin; Kyung-Do Han; Hyuk Yoon; Young Soo Park; Nayoung Kim; Dong Ho Lee
Journal:  J Gastroenterol       Date:  2019-12-02       Impact factor: 7.527

3.  Genetic polymorphisms of NAMPT related with susceptibility to esophageal squamous cell carcinoma.

Authors:  Chuanzhen Zhang; Daojie Yan; Shanshan Wang; Changqing Xu; Wenjun Du; Tao Ning; Changhong Liu; Meijuan Zhang; Ruiping Hou; Ziping Chen
Journal:  BMC Gastroenterol       Date:  2015-04-21       Impact factor: 3.067

4.  Serum leptin levels in gastric cancer patients and the relationship with insulin resistance.

Authors:  Huseyin Begenik; Mehmet Aslan; Ahmet Cumhur Dulger; Habib Emre; Ahu Kemik; Ozgur Kemik; Ramazan Esen
Journal:  Arch Med Sci       Date:  2015-04-23       Impact factor: 3.318

5.  Serum levels of resistin, adiponectin, and apelin in gastroesophageal cancer patients.

Authors:  Dorota Diakowska; Krystyna Markocka-Mączka; Piotr Szelachowski; Krzysztof Grabowski
Journal:  Dis Markers       Date:  2014-06-24       Impact factor: 3.434

6.  Serum adiponectin relates to shortened overall survival in men with squamous cell esophageal cancer treated with preoperative concurrent chemoradiotherapy: a pilot study.

Authors:  Milada Zemanová; Barbora Staňková; Zuzana Ušiakova; Eva Tvrzická; Alexandr Pazdro; Luboš Petruželka; Miroslav Zeman
Journal:  Med Sci Monit       Date:  2014-11-19

Review 7.  Circulating adiponectin levels in various malignancies: an updated meta-analysis of 107 studies.

Authors:  Tai Wei; Peng Ye; Xin Peng; Li-Ling Wu; Guang-Yan Yu
Journal:  Oncotarget       Date:  2016-07-26

8.  Gut hormones, appetite suppression and cachexia in patients with pulmonary TB.

Authors:  Suzanne W Chang; William S Pan; Daniel Lozano Beltran; Lizet Oleyda Baldelomar; Marco Antonio Solano; Iskra Tuero; Jon S Friedland; Faustino Torrico; Robert H Gilman
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

9.  Evolving role of adiponectin in cancer-controversies and update.

Authors:  Arnav Katira; Peng H Tan
Journal:  Cancer Biol Med       Date:  2016-03       Impact factor: 4.248

Review 10.  Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine.

Authors:  Ambra A Grolla; Cristina Travelli; Armando A Genazzani; Jaswinder K Sethi
Journal:  Br J Pharmacol       Date:  2016-06-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.